Dr. Hsiao is the Chief Executive Officer, President, and Co-Founder of Acepodia. Dr. Hsiao has extensive research experience in immune cell therapies, which led to the discovery of components of ACC (Antibody-Cell Conjugation) technology to the invention of the novel cellular immunotherapy ACE (Antibody-Cell Conjugation Effector cells). Dr. Hsiao earned his BS in chemistry from National Taiwan University and his Ph.D. in chemistry and molecular cell biology from the University of California, Berkeley.
.svg)
